- Home
- SPB vs ANAB Comparison
SPB vs ANAB Comparison
Compare SPB & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPB | ANAB |
|---|---|---|
| Founded | 1906 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPB | ANAB |
|---|---|---|
| Price | $75.46 | $65.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $82.40 | $72.60 |
| AVG Volume (30 Days) | 300.8K | ★ 485.8K |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $3,802,100,000.00 | $234,603,000.00 |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $1.85 | $33.49 |
| P/E Ratio | $62.28 | ★ N/A |
| Revenue Growth | 20.86 | ★ 157.01 |
| 52 Week Low | $49.99 | $15.40 |
| 52 Week High | $80.42 | $68.39 |
Technical Indicators
Market Signals| Indicator | SPB | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 64.05 |
| Support Level | $73.99 | $43.67 |
| Resistance Level | $80.42 | $68.39 |
| Average True Range (ATR) | 2.24 | 3.20 |
| MACD | -0.24 | -0.10 |
| Stochastic Oscillator | 82.80 | 82.55 |
Price Performance
Historical ComparisonAbout SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).